Atai Life Sciences (ATAI) said Tuesday the results of a phase 2a study of Beckley Psytech's BPL-003 in patients with moderate to severe alcohol use disorder were encouraging.
The open-label study involved 12 patients, who were given a single dose of BPL-003, in combination with relapse prevention cognitive behavioral therapy, the company said.
The combination resulted in "meaningful and sustained reduction in alcohol use and heavy drinking days" in the 12-week study, it said.
BPL-003 also demonstrated a favorable safety profile, with adverse events characterized as mild or moderate, Atai said.
Beckley Psytech is partly own by Atai.
Atai shares were down more than 3% in recent trading.
Price: 1.40, Change: -0.05, Percent Change: -3.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.